Novo Nordisk’s Wegovy semaglutide has received a label update in Singapore that includes a higher dose. The update is supported by evidence from the STEP UP clinical trial program. The decision was announced on July 8, 2026.
On July 8, 2026, regulatory authorities in Singapore approved an update to the label for Wegovy semaglutide , a medication used for weight management. The updated label now includes information about a higher dose of the drug. This change reflects the latest clinical evidence available for the product.
Wegovy is manufactured by Novo Nordisk and belongs to a class of drugs known as GLP-1 receptor agonists. The medication had previously been approved in Singapore for chronic weight management in adults with obesity or overweight who have at least one weight-related condition.
The specific details of the higher dose were not disclosed in the announcement. However, label updates typically involve changes to dosage recommendations, administration instructions, or safety information. In this case, the inclusion of a higher dose may provide additional treatment options for patients who require greater efficacy or have not achieved sufficient weight loss with lower doses.
Prescribing physicians in Singapore will now be able to consider this higher dose when treating eligible patients. The update also ensures that the product information aligns with the most current scientific understanding of the drug's effects.
The label update is supported by evidence from the STEP UP clinical trial program. STEP UP is a series of studies that evaluated the safety and effectiveness of semaglutide for weight management. The program has previously provided data that supported the initial approval of Wegovy and subsequent label expansions in various countries.
The specific STEP UP study that underpinned the Singapore update was not named in the announcement. However, the evidence from the program is considered robust enough to support a higher dose, suggesting that the clinical data demonstrated favorable benefit-risk profile for the increased dose level.
Label updates are common in the pharmaceutical industry as new data becomes available. The Singapore Health Sciences Authority oversees drug approvals and label changes in the country. By incorporating STEP UP evidence into the Wegovy label, regulators have ensured that healthcare professionals and patients have access to the most up-to-date prescribing information.
This update may also set a precedent for other countries that are reviewing the same clinical evidence. As Novo Nordisk continues to generate data on semaglutide, further label updates in other jurisdictions remain possible.
Peptides referenced: Semaglutide, GLP-1.
Related reading: GLP-1 Drug Exposures to Poison Centers Rise After FDA Weight Loss Approval, FDA Accepts Submissions for Generic Mounjaro and Zepbound, Peptide Exceptionalism as a Dangerous FDA Loophole, Novo Nordisk to Evaluate Semaglutide Implant for Weight Loss.